Novo Nordisk reacts to suspension: "We take the decision very seriously"
Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.
.jpg)
by christian bundgaard, translated by daniel pedersen
The UK’s Prescription Medicines Code of Practice Authority’s (PMCPA) found Danish drugmaker Novo Nordisk’s hidden marketing so problematic it ”brought discredit upon, and reduced confidence in, the pharmaceutical industry,” reads a case report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
UK pharma group suspends Novo Nordisk for two years
For subscribers
.jpg)
Novo Nordisk acknowledges UK marketing violation
For subscribers
.jpg&w=384&q=75)
